We help healthcare providers improve patient care and satisfaction by providing comprehensive molecular testing for viral and bacterial pathogens. Specifically, the presence of Covid-19, influenza A and B as well as other respiratory infections.
Most infections present with similar signs & symptoms. Our targeted approach to infectious disease gives rapid and accurate information to help improve patient management & treatment (such as avoiding unnecessary use of antibiotics). By using a non-invasive, saliva-based, molecular syndromic approach and a broad test menu, Warrior Dx can better detect and identify your patient’s infectious agent with an easy to administer, single-step, saliva diagnostic test.
Pneumonia patients are frequently over-treated with antibiotics because it is difficult to quickly identify the pathogen responsible for their symptoms. Our Pneumonia Panel delivers fast, accurate pathogen identification, which may allow physicians to put patients on appropriate therapy quicker.
The Warrior Dx Pneumonia Panel uses PCR technology to identify nucleic acid for 33 targets – even If an organism will not grow in culture. The most advanced panel to date, it is the only FDA-cleared sample-to-answer assay that tests for 26 pathogens and 7 antibiotic resistance markers associated with pneumonia. It is also the first FDA-cleared molecular test to report semi-quantitative results on 15 bacteria.
A Gastrointestinal PCR Panel Improves Clinical Management and Lowers Health Care Costs
The GI PCR Panel provides diagnosis of infections caused by Campylobacter species, Clostridioides (Clostridium) difficile, Plesiomonas shigelloides, Salmonella species, Vibrio species, V cholerae, Yersinia species, enteroaggregative Escherichia coli, enteropathogenic E coli, enterotoxigenic E coli, Shiga toxin-producing E coli, E coli O157, Shigella/Enteroinvasive E coli, Cryptosporidium species, Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia, adenovirus F 40/41, astrovirus, norovirus, rotavirus, and sapovirus.
Urinary tract infections (UTIs) are among the most common bacterial infections. It has been estimated that symptomatic UTIs result in as many as 7 million visits to outpatient clinics, 1 million visits to emergency departments, and 100,000 hospitalizations annually.
For those patients with complicated UTIs, laboratory tests are necessary to make the diagnosis and to provide specific information regarding the identity and the antimicrobial susceptibility pattern of pathogens.
Accurate and prompt identification and determination of wound pathogens is key to proper wound management for patients suffering from pathogenic infection. The majority of skin wounds are colonized with both aerobic and anaerobic bacteria and yeast.
Wound and skin infections are the growth and spread of microbes, usually bacteria, within the skin or a break or wound in the skin. These infections trigger the body’s immune system and cause inflammation and tissue damage within the skin or wound and slow the healing process.